Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9574 + datopotamab deruxtecan
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
AZD9574 + datopotamab deruxtecan is an experimental combination therapy under investigation for advanced solid tumors. AZD9574 is a selective, blood-brain barrier–penetrant PARP1 (poly ADP-ribose polymerase 1) inhibitor, designed to exploit homologous recombination repair deficiency in cancer cells and shows strong preclinical efficacy, particularly in brain tumors. Datopotamab deruxtecan (Dato-DXd, brand name Datroway) is an antibody-drug conjugate (ADC) consisting of a Trop-2–targeting monoclonal antibody (datopotamab) linked to a topoisomerase I inhibitor (DXd payload), recently FDA-approved for unresectable or metastatic, HR-positive, HER2-negative breast cancer, and accelerated approval for EGFR-mutated non-small cell lung cancer. The combination aims to harness the DNA-damage effects of both agents, potentially increasing antitumor activity in a variety of advanced solid tumors.
- Brand names
- Datroway
- Other names
- Dato-DXdAZD9574 + Dato-DXd
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on AZD9574 + datopotamab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9574 + datopotamab deruxtecan.